Home
CNTX
CNTX News

Latest Context Therapeutics Inc. (CNTX) News on May 10, 2025

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

GlobeNewswire

3 days ago

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

Context Therapeutics Announces Chief Medical Officer Transition

GlobeNewswire

5 days ago

Context Therapeutics Announces Chief Medical Officer Transition

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

GlobeNewswire

10 days ago

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

MT Newswires

19 days ago

William Blair Initiates Context Therapeutics at Outperform

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

GlobeNewswire

a month ago

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos

Zacks

a month ago

Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos

Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains

Zacks

a month ago

Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains

Context Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

a month ago

Context Therapeutics to Participate in Upcoming Investor Conferences

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

GlobeNewswire

a month ago

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth

Simply Wall St.

2 months ago

Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

GlobeNewswire

2 months ago

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

3 months ago

Context Therapeutics to Participate in Upcoming Investor Conferences

Context doses first subject in Phase I cancer trial of CTIM-76

Clinical Trials Arena

4 months ago

Context doses first subject in Phase I cancer trial of CTIM-76

MT Newswires

4 months ago

Context Therapeutics Doses First Patient in Phase 1 Cancer Treatment Trial

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

GlobeNewswire

4 months ago

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

MT Newswires

4 months ago

Context Therapeutics Names Andy Pasternak Board Chairman

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

GlobeNewswire

4 months ago

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

MT Newswires

4 months ago

JMP Securities Initiates Context Therapeutics at Outperform With $4 Price Target

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

GlobeNewswire

6 months ago

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Context Therapeutics to Participate in Upcoming Investor Conferences in November

GlobeNewswire

7 months ago

Context Therapeutics to Participate in Upcoming Investor Conferences in November

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

GlobeNewswire

7 months ago

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

MT Newswires

8 months ago

BioAtla, Context Therapeutics Enter Into License Agreement for BA3362 Cancer Treatment

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

GlobeNewswire

8 months ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

GlobeNewswire

8 months ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth

Simply Wall St.

8 months ago

We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth

Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?

Zacks

8 months ago

Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

GlobeNewswire

8 months ago

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?

Zacks

8 months ago

Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

GlobeNewswire

9 months ago

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Context Therapeutics Inc.'s (NASDAQ:CNTX) top owners are individual investors with 52% stake, while 30% is held by private equity firms

Simply Wall St.

9 months ago

Context Therapeutics Inc.'s (NASDAQ:CNTX) top owners are individual investors with 52% stake, while 30% is held by private equity firms

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

GlobeNewswire

9 months ago

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

MT Newswires

10 months ago

Context Therapeutics Acquires T-cell Engager CT-95 From Link

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

GlobeNewswire

10 months ago

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?

Zacks

a year ago

Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?

MT Newswires

a year ago

Context Therapeutics Files Prospectus for Secondary Offering

Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice

Zacks

a year ago

Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice

Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why

Zacks

a year ago

Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

GlobeNewswire

a year ago

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

GlobeNewswire

a year ago

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

Context Therapeutics Announces $100 Million Private Placement

GlobeNewswire

a year ago

Context Therapeutics Announces $100 Million Private Placement

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

GlobeNewswire

a year ago

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Companies Like Context Therapeutics (NASDAQ:CNTX) Could Be Quite Risky

Simply Wall St.

a year ago

Companies Like Context Therapeutics (NASDAQ:CNTX) Could Be Quite Risky

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

GlobeNewswire

a year ago

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Nutriband CEO Publishes Letter to Shareholders

ACCESSWIRE

a year ago

Nutriband CEO Publishes Letter to Shareholders

Dolphin Entertainment Congratulates 42West and its Clients for Securing 24 Nominations for the 96th Academy Awards

ACCESSWIRE

a year ago

Dolphin Entertainment Congratulates 42West and its Clients for Securing 24 Nominations for the 96th Academy Awards

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

Newsfile

a year ago

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

AMERISERV FINANCIAL REPORTS EARNINGS FOR THE FULL YEAR OF 2023 AND ANNOUNCES QUARTERLY COMMON STOCK CASH DIVIDEND

PR Newswire

a year ago

AMERISERV FINANCIAL REPORTS EARNINGS FOR THE FULL YEAR OF 2023 AND ANNOUNCES QUARTERLY COMMON STOCK CASH DIVIDEND

ElectraMeccanica and Xos Host Joint Investor Call to Provide Shareholder Update

GlobeNewswire

a year ago

ElectraMeccanica and Xos Host Joint Investor Call to Provide Shareholder Update

INNO Holdings and ASP Isotopes Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ACCESSWIRE

a year ago

INNO Holdings and ASP Isotopes Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

PodcastOne (Nasdaq: PODC) Renews Agreement With Award Winning Our Fake History Podcast

NewMediaWire

a year ago

PodcastOne (Nasdaq: PODC) Renews Agreement With Award Winning Our Fake History Podcast

Quantum-Si Introduces World’s First Next-Generation Protein Sequencer™ in Japan with Addition of New Distributor

Business Wire

a year ago

Quantum-Si Introduces World’s First Next-Generation Protein Sequencer™ in Japan with Addition of New Distributor

Autonomous truck developer TuSimple going private

FreightWaves

a year ago

Autonomous truck developer TuSimple going private

GlowLab Collective Joins The Digital Dept. to Launch Specialized Talent Management Division for Skincare Experts and Dermatologists

ACCESSWIRE

a year ago

GlowLab Collective Joins The Digital Dept. to Launch Specialized Talent Management Division for Skincare Experts and Dermatologists

Milestone Scientific CEO Provides Letter to Shareholders; Provides Positive Reimbursement Update

GlobeNewswire

a year ago

Milestone Scientific CEO Provides Letter to Shareholders; Provides Positive Reimbursement Update

Presenting on Emerging Growth Conference 66 Day 2 on January 11 Register to Stream

GlobeNewswire

a year ago

Presenting on Emerging Growth Conference 66 Day 2 on January 11 Register to Stream

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

Business Wire

a year ago

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds

GlobeNewswire

a year ago

Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

GlobeNewswire

a year ago

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

CervoMed to Participate in the Emerging Growth Conference 66

GlobeNewswire

a year ago

CervoMed to Participate in the Emerging Growth Conference 66

Here's Why You Should Invest in Adverum (ADVM) Stock Now

Zacks

a year ago

Here's Why You Should Invest in Adverum (ADVM) Stock Now

Carvana and Carrols Were 2 of the Biggest Winners in 2023, Up Over 1,100% and Over 400%, Respectively. Here Are 3 Stocks With Similar Setups for 2024.

Motley Fool

a year ago

Carvana and Carrols Were 2 of the Biggest Winners in 2023, Up Over 1,100% and Over 400%, Respectively. Here Are 3 Stocks With Similar Setups for 2024.

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

Zacks

a year ago

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study

Zacks

a year ago

argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study

3 Unlikely Companies That Could Be AI Winners in 2024

InvestorPlace

a year ago

3 Unlikely Companies That Could Be AI Winners in 2024

Airspeeder, Veritone and base Revolutionise eVTOL Racing Series With Digital Media Hub Partnership

Business Wire

a year ago

Airspeeder, Veritone and base Revolutionise eVTOL Racing Series With Digital Media Hub Partnership

Perma-Pipe International Holdings (NASDAQ:PPIH) Is Experiencing Growth In Returns On Capital

Simply Wall St.

a year ago

Perma-Pipe International Holdings (NASDAQ:PPIH) Is Experiencing Growth In Returns On Capital

3 Cathie Wood Stocks to Sell Before It’s Too Late

InvestorPlace

a year ago

3 Cathie Wood Stocks to Sell Before It’s Too Late

IPA Announces Pricing of $1.1 Million Public Offering of Common Shares

Business Wire

a year ago

IPA Announces Pricing of $1.1 Million Public Offering of Common Shares

IPA Announces Proposed Public Offering of Common Shares

Business Wire

a year ago

IPA Announces Proposed Public Offering of Common Shares

NeoVolta's Solar Innovation Lights Up the Future: Surpasses 25 Gigawatts in Solar Production

GlobeNewswire

a year ago

NeoVolta's Solar Innovation Lights Up the Future: Surpasses 25 Gigawatts in Solar Production

Selina Hospitality PLC Provides Update Regarding Fundraising and Liability Management Efforts

Business Wire

a year ago

Selina Hospitality PLC Provides Update Regarding Fundraising and Liability Management Efforts

Sonim Technologies to Present at the Sidoti Virtual Investor Conference December 7

Newsfile

a year ago

Sonim Technologies to Present at the Sidoti Virtual Investor Conference December 7

The 3 Best Web3 Stocks to Buy Before Everyone Else Does

InvestorPlace

a year ago

The 3 Best Web3 Stocks to Buy Before Everyone Else Does

Workhorse Group Expands Dealer Network to Eight Partners Nationwide

GlobeNewswire

a year ago

Workhorse Group Expands Dealer Network to Eight Partners Nationwide

ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call

Business Wire

a year ago

ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call

iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease

GlobeNewswire

a year ago

iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease

Analysts Slashing Price Targets During A Quiet Week

Benzinga

a year ago

Analysts Slashing Price Targets During A Quiet Week

Market Sentiment Around Loss-Making NeoVolta Inc. (NASDAQ:NEOV)

Simply Wall St.

a year ago

Market Sentiment Around Loss-Making NeoVolta Inc. (NASDAQ:NEOV)

No One Can Block UCLA Outside Linebacker Laiatu Latu from Getting to Newegg’s Black Friday Sale Featuring Seagate Storage Products

Business Wire

a year ago

No One Can Block UCLA Outside Linebacker Laiatu Latu from Getting to Newegg’s Black Friday Sale Featuring Seagate Storage Products

When Can We Expect A Profit From YS Biopharma Co., Ltd. (NASDAQ:YS)?

Simply Wall St.

a year ago

When Can We Expect A Profit From YS Biopharma Co., Ltd. (NASDAQ:YS)?

Newegg Introduces Group Buy to Reward Customers Who Come Together to Unlock Special Daily Deals

Business Wire

a year ago

Newegg Introduces Group Buy to Reward Customers Who Come Together to Unlock Special Daily Deals

Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for

Zacks

a year ago

Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for

Business Wire

a year ago

Charge Enterprises Appoints Matthew Chee as Senior Vice President of Growth

NeoVolta Reports Q4 Sales Surge As Popular NV14 Home Solar Energy Storage Battery Shows Near Six-Figure Gross Revenues Over Last Six Weeks

GlobeNewswire

a year ago

NeoVolta Reports Q4 Sales Surge As Popular NV14 Home Solar Energy Storage Battery Shows Near Six-Figure Gross Revenues Over Last Six Weeks

What You Need To Know About The Charge Enterprises, Inc. (NASDAQ:CRGE) Analyst Downgrade Today

Simply Wall St.

a year ago

What You Need To Know About The Charge Enterprises, Inc. (NASDAQ:CRGE) Analyst Downgrade Today

Allied Gaming & Entertainment Inc. (NASDAQ:AGAE) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Allied Gaming & Entertainment Inc. (NASDAQ:AGAE) Q3 2023 Earnings Call Transcript

Bragg Gaming Announces Resignation of President and Chief Operating Officer

Business Wire

a year ago

Bragg Gaming Announces Resignation of President and Chief Operating Officer

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

PR Newswire

2 years ago

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

GlobeNewswire

2 years ago

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

GlobeNewswire

2 years ago

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

GlobeNewswire

2 years ago

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

GlobeNewswire

2 years ago

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models

GlobeNewswire

2 years ago

BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models

Share on Social Networks: